BR112016011522A2 - - Google Patents

Info

Publication number
BR112016011522A2
BR112016011522A2 BR112016011522A BR112016011522A BR112016011522A2 BR 112016011522 A2 BR112016011522 A2 BR 112016011522A2 BR 112016011522 A BR112016011522 A BR 112016011522A BR 112016011522 A BR112016011522 A BR 112016011522A BR 112016011522 A2 BR112016011522 A2 BR 112016011522A2
Authority
BR
Brazil
Application number
BR112016011522A
Other languages
Portuguese (pt)
Other versions
BR112016011522B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016011522A2 publication Critical patent/BR112016011522A2/pt
Publication of BR112016011522B1 publication Critical patent/BR112016011522B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112016011522-8A 2013-12-09 2014-12-08 Derivados de imidazotiazol como moduladores de atividade de tnf BR112016011522B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1321731.0 2013-12-09
GBGB1321731.0A GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
PCT/EP2014/076842 WO2015086504A1 (en) 2013-12-09 2014-12-08 Imidazothiazole derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
BR112016011522A2 true BR112016011522A2 (cg-RX-API-DMAC7.html) 2017-08-08
BR112016011522B1 BR112016011522B1 (pt) 2022-10-25

Family

ID=50000414

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011522-8A BR112016011522B1 (pt) 2013-12-09 2014-12-08 Derivados de imidazotiazol como moduladores de atividade de tnf

Country Status (11)

Country Link
US (1) US10273247B2 (cg-RX-API-DMAC7.html)
EP (1) EP3080133B1 (cg-RX-API-DMAC7.html)
JP (1) JP6483700B2 (cg-RX-API-DMAC7.html)
CN (1) CN105814065B (cg-RX-API-DMAC7.html)
BR (1) BR112016011522B1 (cg-RX-API-DMAC7.html)
CA (1) CA2930912C (cg-RX-API-DMAC7.html)
ES (1) ES2743190T3 (cg-RX-API-DMAC7.html)
GB (1) GB201321731D0 (cg-RX-API-DMAC7.html)
RU (1) RU2683940C1 (cg-RX-API-DMAC7.html)
TR (1) TR201910983T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015086504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3286195A1 (en) 2015-04-17 2018-02-28 AbbVie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TW201920202A (zh) * 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
US20240002401A1 (en) * 2020-11-16 2024-01-04 Guangzhou Henovcom Bioscience Co., Ltd. Imidazothiazole compounds, pharmaceutical compositions, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463212A1 (en) * 1990-06-27 1992-01-02 Nikken Chemicals Co., Ltd. Imidazo[2,1-b]thiazole compound anti-ulcer agent containing the same
US5577987A (en) 1994-07-07 1996-11-26 Precise Exercise Equipment Co. Abdominal exerciser device
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
JP2002167389A (ja) * 2000-09-20 2002-06-11 Nikken Chem Co Ltd 新規チアゾールニ環化合物
CA2523336A1 (en) * 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
CN1823072A (zh) * 2003-05-15 2006-08-23 艾科尔公司 作为p38抑制剂的咪唑并噻唑和咪唑并噁唑衍生物
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
WO2011132048A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
EP3080133A1 (en) 2016-10-19
US20160376290A1 (en) 2016-12-29
ES2743190T3 (es) 2020-02-18
CN105814065B (zh) 2018-11-23
TR201910983T4 (tr) 2019-08-21
CN105814065A (zh) 2016-07-27
JP6483700B2 (ja) 2019-03-13
GB201321731D0 (en) 2014-01-22
US10273247B2 (en) 2019-04-30
RU2683940C1 (ru) 2019-04-03
WO2015086504A1 (en) 2015-06-18
RU2016127226A (ru) 2018-01-23
EP3080133B1 (en) 2019-07-10
CA2930912A1 (en) 2015-06-18
BR112016011522B1 (pt) 2022-10-25
JP2016539968A (ja) 2016-12-22
CA2930912C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC7.html)
BR112015007533A2 (cg-RX-API-DMAC7.html)
BR112014017733A2 (cg-RX-API-DMAC7.html)
BR112014017739A2 (cg-RX-API-DMAC7.html)
BR112014019326A2 (cg-RX-API-DMAC7.html)
BR112014018502A2 (cg-RX-API-DMAC7.html)
BR112014018516A2 (cg-RX-API-DMAC7.html)
BR112014017765A2 (cg-RX-API-DMAC7.html)
BR112014018480A2 (cg-RX-API-DMAC7.html)
BR112014017855A2 (cg-RX-API-DMAC7.html)
BR112014020341A2 (cg-RX-API-DMAC7.html)
BR112016003424A2 (cg-RX-API-DMAC7.html)
BR112014021878A2 (cg-RX-API-DMAC7.html)
BR112014018468A2 (cg-RX-API-DMAC7.html)
BR112014018207A2 (cg-RX-API-DMAC7.html)
BR112014019204A2 (cg-RX-API-DMAC7.html)
BR112016001295A2 (cg-RX-API-DMAC7.html)
BR112014017901A2 (cg-RX-API-DMAC7.html)
BR112014017745A2 (cg-RX-API-DMAC7.html)
BR112014018483A2 (cg-RX-API-DMAC7.html)
BR112014017722A2 (cg-RX-API-DMAC7.html)
BR112014017794A2 (cg-RX-API-DMAC7.html)
BR112014017653A2 (cg-RX-API-DMAC7.html)
BR112014018578A2 (cg-RX-API-DMAC7.html)
BR112014017601A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFIQUE-SE, POR INCORRECOES NO QUADRO 1

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2752 DE 03-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.